After holding a ringside seat watching the growing team at BlueRock build up an advanced preclinical set of regenerative stem cell projects in the pipeline, Bayer wants to own it all. Bayer execs struck a deal to buy out the 60% of the shares it didn’t already own, paying $240 million in cash and setting […]